The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Tadalafil Therapy for Pulmonary Arterial Hypertension
Abstract
Background— Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway. Methods and Results— In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily. The primary end point was the change from baseline to week 16 in the distance walked in 6 minutes. Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients completing the 16-week study could enter a long-term extension study. Tadalafil increased the distance walked in 6 minutes in a dose-dependent manner; only the 40-mg dose met the prespecified level of statistical significance ( P <0.01). Overall, the mean placebo-corrected treatment effect was 33 m (95% confidence interval, 15 to 50 m). In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m) compared with 23 m (95% confidence interval, −2 to 48 m) in patients on background bosentan therapy. Tadalafil 40 mg improved the time to clinical worsening ( P =0.041), incidence of clinical worsening (68% relative risk reduction; P =0.038), and health-related quality of life. The changes in World Health Organization functional class were not statistically significant. The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing. Conclusions— In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Self-citationSildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Self-citationThe 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. (1985) · Europe PMC (PubMed Central) · Cited by 2,401
Inhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationPrimary Pulmonary Hypertension
Rubin, L. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360207 · Cited by 1,726
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Self-citationCellular and molecular pathobiology of pulmonary arterial hypertension
Humbert, M., Morrell, N. W., Archer, S. L., Stenmark, K. R., MacLean, M. R., Lang, I. M., Christman, B. W., Weir, E. K., Eickelberg, O., Voelkel, N. F., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.029 · Cited by 1,576
Channick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06250-x · Cited by 1,534
Self-citationPulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Self-citationGiaid, A., & Saleh, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507273330403 · Cited by 1,369
Galiè, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.742510 · Cited by 1,083
Self-citationDiagnosis and differential assessment of pulmonary arterial hypertension
Barst, R. J., McGoon, M., Torbicki, A., Sitbon, O., Krowka, M. J., Olschewski, H., & Gaine, S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.032 · Cited by 992
Self-citationGaliè, N., Rubin, L., Hoeper, M., Jansa, P., Al-Hiti, H., Meyer, G., Chiossi, E., Kusic-Pajic, A., & Simonneau, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60919-8 · Cited by 920
Self-citationMedical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · Chest · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
Self-citationPathologic assessment of vasculopathies in pulmonary hypertension
Pietra, G. G., Capron, F., Stewart, S., Leone, O., Humbert, M., Robbins, I. M., Reid, L. M., & Tuder, R. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.033 · Cited by 709
Sitaxsentan Therapy for Pulmonary Arterial Hypertension
Barst, R. J., Langleben, D., Frost, A., Horn, E. M., Oudiz, R., Shapiro, S., McLaughlin, V., Hill, N., Tapson, V. F., Robbins, I. M., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-957oc · Cited by 706
Self-citationRandomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H., & Rubin, L. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-358oc · Cited by 626
Self-citationSimonneau, G., Rubin, L. J., Galiè, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00004 · Cited by 616
Self-citationMichelakis, E., Tymchak, W., Lien, D., Webster, L., Hashimoto, K., & Archer, S. (2002) · Circulation · doi:10.1161/01.cir.0000016641.12984.dc · Cited by 577
Ambrisentan Therapy for Pulmonary Arterial Hypertension
Galié, N., Badesch, D., Oudiz, R., Simonneau, G., McGoon, M. D., Keogh, A. M., Frost, A. E., Zwicke, D., Naeije, R., Shapiro, S., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.050 · Cited by 494
Self-citationClinical efficacy of sildenafil in primary pulmonary hypertension
Sastry, B. K. S., Narasimhan, C., Reddy, N. K., & Raju, B. S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.056 · Cited by 488
Barst, R. J., Langleben, D., Badesch, D., Frost, A., Lawrence, E. C., Shapiro, S., Naeije, R., & Galie, N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.057 · Cited by 478
Self-citationMedical Therapy for Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Simonneau, G., Rubin, L. J., & McLaughlin, V. V. (2007) · Chest · doi:10.1378/chest.06-2674 · Cited by 438
Self-citationAntiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells
Wharton, J., Strange, J. W., Møller, G. M. O., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C., & Wilkins, M. R. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1587oc · Cited by 371
Ghofrani, H. A., Voswinckel, R., Reichenberger, F., Olschewski, H., Haredza, P., Karadaş, B., Schermuly, R. T., Weissmann, N., Seeger, W., & Grimminger, F. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.060 · Cited by 286
Self-citationSingh, T. P., Rohit, M., Grover, A., Malhotra, S., & Vijayvergiya, R. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.09.006 · Cited by 263
High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors
Corbin, J. D., Beasley, A., Blount, M. A., & Francis, S. H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.183 · Cited by 205
Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells
Tantini, B., Manes, A., Fiumana, E., Pignatti, C., Guarnieri, C., Zannoli, R., MD, A. B., & Gali�, N. (2005) · Basic Research in Cardiology · doi:10.1007/s00395-004-0504-5 · Cited by 191
Frost, A. E., Langleben, D., Oudiz, R., Hill, N., Horn, E., McLaughlin, V., Robbins, I. M., Shapiro, S., Tapson, V. F., Zwicke, D., et al. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.03.003 · Cited by 190
Self-citationMutual pharmacokinetic interactions between steady-state bosentan and sildenafil
Burgess, G., Hoogkamer, H., Collings, L., & Dingemanse, J. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0408-z · Cited by 151
Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects
Wrishko, R. E., Dingemanse, J., Yu, A., Darstein, C., Phillips, D. L., & Mitchell, M. I. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008315315 · Cited by 118
Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension
Archer, S. L., Djaballah, K., Humbert, M. J. C., Weir, Ε. K., Fartoukh, M. S., DALL'AVA-SANTUCCI, J., Mercier, J., Simonneau, G., & Dinh‐Xuan, A. T. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.4.9802113 · Cited by 112
Self-citationSildenafil Improves Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension*
Pepke‐Żaba, J., Gilbert, C. E., Collings, L., & Brown, M. C. J. (2008) · CHEST Journal · doi:10.1378/chest.07-0592 · Cited by 96
Tadalafil in Primary Pulmonary Arterial Hypertension
Palmieri, E. A., Affuso, F., Fazio, S., & Lembo, D. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-9-200411020-00033 · Cited by 46
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Self-citation
Metadata
- Authors
- Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., Frumkin, L., & Barst, R. J.
- Venue
- Circulation
- Published
- 2009-06-09
- Volume
- 119
- Issue
- 22
- Pages
- 2894-2903
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2148038451
- Cited by
- 1,103
- References
- 37
- FWCI
- 72.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.